Pyridinylimidazole inhibitors of Tie2 kinase
M Semones, Y Feng, N Johnson, JL Adams… - Bioorganic & medicinal …, 2007 - Elsevier
M Semones, Y Feng, N Johnson, JL Adams, J Winkler, M Hansbury
Bioorganic & medicinal chemistry letters, 2007•ElsevierThis communication details the evolution of the screening lead SB-203580, a known
CSBP/p38 kinase inhibitor, into a potent and selective Tie2 tyrosine kinase inhibitor. The
optimized compound 5 showed efficacy in an in vivo model of angiogenesis and a MOPC-
315 plasmacytoma xenograft model.
CSBP/p38 kinase inhibitor, into a potent and selective Tie2 tyrosine kinase inhibitor. The
optimized compound 5 showed efficacy in an in vivo model of angiogenesis and a MOPC-
315 plasmacytoma xenograft model.
This communication details the evolution of the screening lead SB-203580, a known CSBP/p38 kinase inhibitor, into a potent and selective Tie2 tyrosine kinase inhibitor. The optimized compound 5 showed efficacy in an in vivo model of angiogenesis and a MOPC-315 plasmacytoma xenograft model.
Elsevier